Pathogen Inactivation
Program Code: 219-S
Sunday, October 16, 2005
10:30 AM to 12:00 PM (ET)

MODERATOR
Harvey G. Klein, MD, National Institutes of Health

SPEAKERS
Stephen Wagner, PhD, American Red Cross
Raymond Goodrich, PhD, Navigant Biotechnologies, LLC
Bernard Horowitz, PhD

DESCRIPTION
Although the infectious risks of blood transfusion are remarkably small, the current multi-layered approach of donor screening, testing, deferral registries, and postdonation tracking will not likely have as much impact in the future as it had in the past. Pathogen inactivation technologies have all but eliminated the infectious risks of plasma-derived protein fractions. This session will concentrate on the issues surrounding pathogen inactivation of blood components and how they contrast with those involved in plasma fraction manufacturing.